Online Investor Kit

Assemble your own Investor Kit by selecting and printing from the following documents.

Corporate Presentation

Date Documents

Recent SEC Filings

Filing date Form Description Filing Group Downloads
4

Statement of changes in beneficial ownership of securities
3,4,5
0001396814-24-000037.rtf
0001396814-24-000037.xls
0001396814-24-000037.pdf
144

Filed by "insiders" prior intended sale of restricted stock. Non-EDGAR filing
Other
0002007317-24-000320.rtf
0002007317-24-000320.xls
0002007317-24-000320.pdf
8-K

Report of unscheduled material events or corporate event
Current Reports
0001396814-24-000026.rtf
0001396814-24-000026.xls
0001396814-24-000026.pdf
10-K

Annual report which provides a comprehensive overview of the company for the past year
Annual Filings
0001396814-24-000030.rtf
0001396814-24-000030.xls
0001396814-24-000030.pdf
S-8

Securities offered to employees pursuant to employee benefit plans
Registration Statements
0001396814-24-000035.rtf
0001396814-24-000035.xls
0001396814-24-000035.pdf

Fact Sheets

There are currently no items available.

Recent Press Releases

Date Title and Summary
Toggle Summary Pacira BioSciences to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
TAMPA, Fla., April 02, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the 23 rd Annual Needham Virtual Healthcare Conference at 8:00 AM ET on Monday, April 8, 2024.
Toggle Summary Pacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy (RMAT) Designation for the Treatment of Osteoarthritis of the Knee
-- PCRX-201 is the first gene therapy product candidate to receive RMAT designation for osteoarthritis -- -- Designation supported by encouraging preliminary data from 72-patient Phase 1 study -- -- 52-Week Data Accepted for Presentation at OARSI 2024 and 104-week data to be submitted for
Toggle Summary Pacira BioSciences to Participate in Fireside Chat at the Barclays 26th Annual Global Healthcare Conference
TAMPA, Fla., March 06, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the Barclays 26 th Annual Global Healthcare Conference at 1:35 PM ET on Wednesday, March 13, 2024 in Miami.
Toggle Summary Pacira BioSciences Reports Fourth Quarter and Full-Year 2023 Financial Results
— Record revenues of $675 million in 2023 — — Full-year GAAP net income of $42 million and adjusted EBITDA of $214 million — — EXPAREL surpasses the 14 million patient mark — — Conference call today at 8:30 a.m. ET — TAMPA, Fla., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc.
Toggle Summary Pacira to Report 2023 Financial Results on Thursday February 29, 2024
TAMPA, Fla., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its fourth quarter and year ended December 31, 2023 financial results before the open of the U.S. markets on Thursday February 29, 2024.
Toggle Summary Pacira Announces Publication of Pivotal Study of EXPAREL as a Sciatic Nerve Block in the Popliteal Fossa for Patients After Bunionectomy
– Findings demonstrate significant reduction in pain and opioid consumption through 96 hours versus active comparator – – Significantly greater proportion of opioid-free patients receiving EXPAREL – TAMPA, Fla., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc., (Nasdaq: PCRX), the
Toggle Summary Pacira BioSciences Awarded Brand Pharmaceuticals Agreement With Premier, Inc.
TAMPA, Fla., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc., (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, has been awarded a national group purchasing agreement for Brand Pharmaceuticals with Premier, Inc.
Toggle Summary Pacira Reports Preliminary Unaudited Fourth Quarter and Full-Year 2023 Revenues
TAMPA, Fla., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported preliminary unaudited total revenue of $675.0 million for the year ended December 31, 2023,
Toggle Summary Pacira BioSciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference
TAMPA, Fla., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will present at the 42 nd Annual J.P. Morgan Healthcare Conference at 8:15 AM PT (11:15 AM EST) on Wednesday, January 10, 2024. Live audio of the event can be accessed by visiting the
Toggle Summary Pacira Appoints Frank D. Lee as Chief Executive Officer
-- Transformational Leader Brings Three Decades of Global Experience in Pharmaceutical and Biotechnology Product Development and Commercialization -- -- Paul J. Hastings Named Chair of the Board -- -- Dave Stack to Remain in Advisory Role through August 2025 -- TAMPA, Fla., Dec.